NASDAQ:ACAD

Acadia Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy ACAD

*Your capital is at risk

$21.43

+0.540 (+2.58%)

At Close: Jun 03, 2026

ACADIA Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 4.71. In total, the insiders bought 1.41M and sold 147.72K ACAD shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	4.71
● Buy	1.41M shares
● Sell	147.72K shares
76% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Mar 25, 2026 Analysis Breakdown: Weakened by a contradictory positive Insider Power Score. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 25, 2026 Buy	Restricted Stock Units M-Exempt	Kihara James Principal Accounting Officer	Officer	2 142 Value: $47.1K
Mar 25, 2026 Buy	Common Stock M-Exempt	Schneyer Mark C. EVP, Chief Financial Officer	C-Suite Officer	6 178 Value: $136.0K
Mar 25, 2026 Sell	Common Stock S-Sale	Schneyer Mark C. EVP, Chief Financial Officer	C-Suite Officer	4 177 Value: $89.7K
Mar 24, 2026 Buy	Common Stock M-Exempt	Thompson Elizabeth H.z. EVP, Head Of Research & Dev	Officer	6 715 Value: $140.7K
Mar 24, 2026 Buy	Common Stock M-Exempt	Rhodes Jennifer J EVP, Chief Legal Officer, Sec	Officer	7 515 Value: $157.5K
Mar 24, 2026 Buy	Common Stock M-Exempt	Owen Adams Catherine Chief Executive Officer	CEO / President	23 509 Value: $492.7K
Mar 24, 2026 Buy	Restricted Stock Units M-Exempt	Owen Adams Catherine Chief Executive Officer	CEO / President	23 509 Value: $492.7K
Mar 24, 2026 Buy	Restricted Stock Units M-Exempt	Rhodes Jennifer J EVP, Chief Legal Officer, Sec	Officer	7 515 Value: $157.5K
Mar 24, 2026 Buy	Restricted Stock Units M-Exempt	Thompson Elizabeth H.z. EVP, Head Of Research & Dev	Officer	6 715 Value: $140.7K
Mar 24, 2026 Buy	Common Stock M-Exempt	Kihara James Principal Accounting Officer	Officer	1 627 Value: $34.1K
Mar 24, 2026 Buy	Restricted Stock Units M-Exempt	Kihara James Principal Accounting Officer	Officer	1 627 Value: $34.1K
Mar 24, 2026 Buy	Common Stock M-Exempt	Schneyer Mark C. EVP, Chief Financial Officer	C-Suite Officer	8 138 Value: $170.6K
Mar 24, 2026 Buy	Restricted Stock Units M-Exempt	Schneyer Mark C. EVP, Chief Financial Officer	C-Suite Officer	8 138 Value: $170.6K
Mar 06, 2026 Buy	Stock Option (Right to Buy) A-Award	Garner Thomas EVP, Chief Commercial Officer	Officer	97 947 Value: $2.17M
Mar 06, 2026 Buy	Restricted Stock Units A-Award	Schneyer Mark C. EVP, Chief Financial Officer	C-Suite Officer	26 382 Value: $584.6K
Mar 06, 2026 Buy	Stock Option (Right to Buy) A-Award	Schneyer Mark C. EVP, Chief Financial Officer	C-Suite Officer	90 691 Value: $2.01M
Mar 06, 2026 Buy	Restricted Stock Units A-Award	Rhodes Jennifer J EVP, Chief Legal Officer, Sec	Officer	26 382 Value: $584.6K
Mar 06, 2026 Buy	Stock Option (Right to Buy) A-Award	Rhodes Jennifer J EVP, Chief Legal Officer, Sec	Officer	90 691 Value: $2.01M
Mar 06, 2026 Buy	Restricted Stock Units A-Award	Kihara James Principal Accounting Officer	Officer	6 332 Value: $140.3K
Mar 06, 2026 Buy	Stock Option (Right to Buy) A-Award	Kihara James Principal Accounting Officer	Officer	21 766 Value: $482.3K
Mar 06, 2026 Buy	Restricted Stock Units A-Award	Garner Thomas EVP, Chief Commercial Officer	Officer	28 493 Value: $631.4K
Mar 06, 2026 Buy	Stock Option (Right to Buy) A-Award	Thompson Elizabeth H.z. EVP, Head Of Research & Dev	Officer	101 574 Value: $2.25M
Mar 06, 2026 Buy	Restricted Stock Units A-Award	Thompson Elizabeth H.z. EVP, Head Of Research & Dev	Officer	29 548 Value: $654.8K
Mar 06, 2026 Buy	Stock Option (Right to Buy) A-Award	Owen Adams Catherine Chief Executive Officer	CEO / President	263 005 Value: $5.83M
Mar 06, 2026 Buy	Restricted Stock Units A-Award	Owen Adams Catherine Chief Executive Officer	CEO / President	76 509 Value: $1.70M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ACADIA PHARMACEUTICALS INC.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psych...

Read Full Profile Here